Tania Jaber1, Steven G Waguespack1, Maria E Cabanillas1, Mohamed Elbanan2, Thinh Vu3, Ramona Dadu1, Steven I Sherman1, Moran Amit4, Elmer B Santos5, Mark Zafereo4, Naifa L Busaidy1. 1. Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Quantitative Imaging Analysis Core, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
Context: Many differentiated thyroid cancers (DTC) dedifferentiate and become radioactive iodine (RAI)-refractory (RAIR) with worse outcomes. Targeted therapy (TTx) may downregulate MAPK signaling and sensitize tumors to RAI. Objective: We describe patients with RAIR DTC receiving TTx with demonstrated RAI uptake allowing for iodine-131 (I131) administration. Design: Charts of patients with metastatic, progressive, RAIR DTC in whom TTx increased RAI uptake on a diagnostic whole-body scan (WBS), were reviewed. Results of WBS, I131 administration, thyroglobulin (TG) panels, and cross-sectional studies were recorded. Setting: Thirteen patients [median age (range), 56 (45 to 75) years; seven men] were included; 11 (85%) had DTC, two (15%) had poorly DTC. Nine (69%) had BRAF mutations, three (23%) had RAS mutations, and one (8%) was wild type. Selective BRAF or an MEK inhibitor TTx was continued for a median (range) of 14.3 (1 to 76.4) months before diagnostic WBS. Results: Nine (69%) patients were treated with I131 [median (range) activity, 204.4 (150 to 253) mCi], after which TTx was discontinued. Median (range) follow-up was 8.3 (0 to 17.4) months after I131 therapy. All nine patients had durable disease control (three had partial response, six had stable disease). TG and TG antibody levels increased in patients who demonstrated uptake before TTx, and declined in eight of the nine patients after I131 treatment. Adverse events included pneumonitis and sialadenitis. Conclusion: TTx in BRAF-/RAS-mutated RAIR DTC resensitizes tumors to iodine. Subsequent I131 administration results in meaningful responses. Patient selection, adverse events, response duration, and survival impact require additional study.
Context: Many differentiated thyroid cancers (DTC) dedifferentiate and become radioactive iodine (RAI)-refractory (RAIR) with worse outcomes. Targeted therapy (TTx) may downregulate MAPK signaling and sensitize tumors to RAI. Objective: We describe patients with RAIR DTC receiving TTx with demonstrated RAI uptake allowing for iodine-131 (I131) administration. Design: Charts of patients with metastatic, progressive, RAIR DTC in whom TTx increased RAI uptake on a diagnostic whole-body scan (WBS), were reviewed. Results of WBS, I131 administration, thyroglobulin (TG) panels, and cross-sectional studies were recorded. Setting: Thirteen patients [median age (range), 56 (45 to 75) years; seven men] were included; 11 (85%) had DTC, two (15%) had poorly DTC. Nine (69%) had BRAF mutations, three (23%) had RAS mutations, and one (8%) was wild type. Selective BRAF or an MEK inhibitor TTx was continued for a median (range) of 14.3 (1 to 76.4) months before diagnostic WBS. Results: Nine (69%) patients were treated with I131 [median (range) activity, 204.4 (150 to 253) mCi], after which TTx was discontinued. Median (range) follow-up was 8.3 (0 to 17.4) months after I131 therapy. All nine patients had durable disease control (three had partial response, six had stable disease). TG and TG antibody levels increased in patients who demonstrated uptake before TTx, and declined in eight of the nine patients after I131 treatment. Adverse events included pneumonitis and sialadenitis. Conclusion:TTx in BRAF-/RAS-mutated RAIR DTC resensitizes tumors to iodine. Subsequent I131 administration results in meaningful responses. Patient selection, adverse events, response duration, and survival impact require additional study.
Authors: Jonas A de Souza; Bonnie J Yap; Fay J Hlubocky; Kristen Wroblewski; Mark J Ratain; David Cella; Christopher K Daugherty Journal: Cancer Date: 2014-06-20 Impact factor: 6.860
Authors: Debyani Chakravarty; Elmer Santos; Mabel Ryder; Jeffrey A Knauf; Xiao-Hui Liao; Brian L West; Gideon Bollag; Richard Kolesnick; Tin Htwe Thin; Neal Rosen; Pat Zanzonico; Steven M Larson; Samuel Refetoff; Ronald Ghossein; James A Fagin Journal: J Clin Invest Date: 2011-11-21 Impact factor: 14.808
Authors: S Yousuf Zafar; Rebecca B McNeil; Catherine M Thomas; Christopher S Lathan; John Z Ayanian; Dawn Provenzale Journal: J Oncol Pract Date: 2014-12-16 Impact factor: 3.840
Authors: Scott D Ramsey; Aasthaa Bansal; Catherine R Fedorenko; David K Blough; Karen A Overstreet; Veena Shankaran; Polly Newcomb Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Jonas A de Souza; Bonnie J Yap; Kristen Wroblewski; Victoria Blinder; Fabiana S Araújo; Fay J Hlubocky; Lauren H Nicholas; Jeremy M O'Connor; Bruce Brockstein; Mark J Ratain; Christopher K Daugherty; David Cella Journal: Cancer Date: 2016-10-07 Impact factor: 6.860
Authors: Marie-Claude Hofmann; Muthusamy Kunnimalaiyaan; Jennifer R Wang; Naifa L Busaidy; Steven I Sherman; Stephen Y Lai; Mark Zafereo; Maria E Cabanillas Journal: Endocr Relat Cancer Date: 2022-09-14 Impact factor: 5.900
Authors: Myat Han Soe; Janet M Chiang; Robert R Flavell; Elham Khanafshar; Laura Mendoza; Hyunseok Kang; Chienying Liu Journal: J Clin Endocrinol Metab Date: 2022-07-14 Impact factor: 6.134
Authors: David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph Journal: Head Neck Date: 2022-03-11 Impact factor: 3.821
Authors: Vatche Tchekmedyian; Lara Dunn; Eric Sherman; Shrujal S Baxi; Ravinder K Grewal; Steven M Larson; Keith S Pentlow; Sofia Haque; R Michael Tuttle; Mona M Sabra; Stephanie Fish; Laura Boucai; Jamie Walters; Ronald A Ghossein; Venkatraman E Seshan; Jeffrey A Knauf; David G Pfister; James A Fagin; Alan L Ho Journal: Thyroid Date: 2022-03 Impact factor: 6.506